Suvretta Capital Management LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Suvretta Capital Management LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 17,888 shares of the biotechnology company’s stock, valued at approximately $2,175,000.

Other institutional investors also recently added to or reduced their stakes in the company. Manchester Capital Management LLC increased its position in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares during the period. Newbridge Financial Services Group Inc. bought a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $36,000. Steward Partners Investment Advisory LLC increased its holdings in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 194 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Sarepta Therapeutics by 95.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 216 shares during the period. 86.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

SRPT has been the topic of several research reports. Evercore ISI downgraded shares of Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price objective on the stock. in a report on Thursday, May 8th. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Oppenheimer dropped their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. HC Wainwright dropped their price objective on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Finally, Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.74.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $36.43 on Friday. The firm has a market cap of $3.58 billion, a PE ratio of 29.14 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 12 month low of $34.10 and a 12 month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company’s 50-day moving average price is $60.11 and its two-hundred day moving average price is $97.59.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. Sarepta Therapeutics’s quarterly revenue was up 80.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.